Glenmark takes crofelemer into Indian Phase III study for adult diarrhoea
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals is moving forward with a Phase III study in India with the anti-secretary gastrointestinal agent, crofelemer, which is currently at the centre of a dispute with Napo Pharmaceuticals.